Skip navigation
Skip navigation

Loss of response to infliximab is common amongst patients with inflammatory bowel disease and varies according to definition

Sivanes, S; Davenport, A; Gupta, Arun

Description

Background: Loss of response (LOR) to infliximab (IFX) is common amongst patients with inflammatory bowel disease (IBD); however, there is heterogeneity as to how LOR is defined. Roda et al. (2016) suggest that LOR may be defined according to recurrence of symptoms, or alternatively only when there is objective evidence of recurrent disease, or only when a change in biologic was instituted.1 Aims: To assess the rate of LOR to IFX amongst patients with IBD treated at a tertiary referral...[Show more]

CollectionsANU Research Publications
Date published: 2016
Type: Conference paper
URI: http://hdl.handle.net/1885/267259
Source: Journal of Gastroenterology and Hepatology
DOI: 10.1111/jgh.13590
Access Rights: Free Access via publisher website

Download

File Description SizeFormat Image
01_Sivanes_Loss_of_response_to_infliximab_2016.pdf1.75 MBAdobe PDF    Request a copy


Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.

Updated:  17 November 2022/ Responsible Officer:  University Librarian/ Page Contact:  Library Systems & Web Coordinator